Assessing risk factors for overweight among people living with HIV transitioning to post-dolutegravir-based regimens in Homa Bay County, Kenya
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20262222Keywords:
Dolutegravir, ART, Weight gain, Overweight, People living with HIV, Non-communicable diseasesAbstract
Background: Viral suppression and treatment outcomes have significantly improved for people living with HIV (PLHIV) on Dolutegravir (DTG)-based regimens. More recently, however, there has been evidence that DTGs are associated with weight gain and therefore overweight and obesity, and the associated non-communicable diseases. The aim of this study was to evaluate risk factors for overweight in PLHIV transitioned onto DTG-based regimens in Homa Bay County in Kenya.
Methods: A mixed-methods study that combined retrospective cohort and cross-sectional approach was used on PLHIV aged ≥18 years receiving DTG-based regimens for ≥6 months in 7 public health facilities in Homa Bay county. Data was collected on 540 people (90% response rate) using medical record review, structured questionnaires and a food frequency questionnaire. SPSS 27 was used to perform descriptive statistics, chi-square tests, Pearson's correlation, t test, and multivariate regression.
Results: The results indicated that 4.2 kg weight gain occurred after transition to the DTG-based regimens. There was more weight gain in female participants than in male. Socio-demographic characteristics (χ²=18.6, p=0.005; r=0.41, p=0.01), dietary factors (r=0.47, p<0.001) and medication adherence (r=0.41, p=0.01) were significantly associated with weight gain.
Conclusions: Socio-demographic factors, dietary patterns and treatment adherence significantly influenced weight gain in PLHIV on DTG-based treatment. Clinically embedding chronic disease monitoring, nutrition counseling and non-communicable disease testing into HIV care could help manage downstream health implications.
References
UNAIDS. AIDS, crisis, and the power to transform. In: Joint United Nations Programme on HIV/AIDS. 2025.
Masaba RO, Herrera N, Siamba S, Ouma M, Okal C, Mayi A, et al. Advanced HIV disease in Homa Bay County, Kenya: Characteristics of newly-diagnosed and antiretroviral therapy-experienced clients. Medicine. 2023;102(51):e36716.
Brennan AT, Nattey C, Kileel EM, Rosen S, Maskew M, Stokes AC, et al. Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa. eClinicalMedicine. 2023;6(7):101836.
Dravid A, Morkar D, Prasad D, RamapuraM ohn T, Patel KV, Aik KSN, et al. A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1. Pragmat Obs Res. 2022;13:75-84.
Koliaki C, Spinos T, Spinou Μ, Brinia ΜE, Mitsopoulou D, Katsilambros N. Defining the Optimal Dietary Approach for Safe, Effective and Sustainable Weight Loss in Overweight and Obese Adults. Healthcare Basel. 2018;6(3):73.
Han WM, Law MG, Choi JY, Ditangco R, Kumarasamy N, Chaiwarith R, et al. Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Medicine. 2022;23(3):274-86.
Adal M, Howe R, Kassa D, Aseffa A, Petros B. Malnutrition and lipid abnormalities in antiretroviral naïve HIV-infected adults in Addis Ababa: A cross-sectional study. PLoS One. 2018;13(4):e0195942.
Esber AL, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J, et al. Weight gain during the dolutegravir transition in the African Cohort Study. J Int AIDS Society. 2022;25(4):e25899.
Hickey MD, Wafula E, Ogachi SM, Ojwando H. Weight Change Following Switch to Dolutegravir for HIV Treatment in Rural Kenya During Country Roll-Out. J Acqui Immune Defic Syndr. 2023;93(2):154-61.
Ando N, Nishijima T, Mizushima D, Inaba Y, Kawasaki Y, Kikuchi Y, et al. Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus. Int J Infect Dis. 2021;110:21-8.
Kilapilo MS, Sangeda RZ, Killewo J. Adherence to Antiretroviral Therapy and Associated Factors Among People Living with HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania. J Int Assoc Providers AIDS Care. 2022;21:23259582221084543.
Alookaran J, Rehman A. Weight Gain Prevention Strategies. StatPearls Publishing. 2023.
KeHMIS. Kenya Health Management Information System. Data warehouse. 2024. Available at: https://kenyahmis.org/documentation/summary-national-data-warehouse/. Accessed on 19 June 2026.
Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, Wyk-Heath M van, Mthethwa S, et al. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024;25(6):826-39.
Kasibante NM, Tokema N, Kilama AD, Mpuuga M, Pitua I, Okot J, et al. Prevalence of Weight Gain and Associated Factors Among People Living with HIV 6- and 12-Months Post Dolutegravir-Based Anti-Retroviral Regimen Initiation in Gulu, Uganda; A Hospital-Based Retrospective Cohort Study. HIV AIDS. 2025;17:361-72.
Bourgi K, Ofner S, Musick B, Griffith B, Diero L, Wools-Kaloustian K, et al. Weight Gain Among Treatment-Naïve Persons with HIV Receiving Dolutegravir in Kenya. J Acqui Immune Defic Synd. 2022;91(5):490-6.
McCluskey SM, Pepperrell T, Hill A, Venter WDF, Gupta RK, Siedner MJ. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021;35(2):S127-35.
Wiriyatanakorn S, Sungkanuparph S. Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients with Virological Suppression: A Randomized Controlled Trial. Open Forum Infect Dis. 2019;6(7):ofz297.
Downloads
Published
How to Cite
Issue
Section
